The conventional assessment methodologies, which predominantly utilize clinical pathological attributes such as tumor size, grade of differentiation, and receptor status including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), are insufficient to capture the heterogeneity of individual patients and the complexities inherent to tumor biology (2, 3). This evidence concerns the gene PGR and neoplasm.